DRL Vs Ranbaxy Pharmaceutical Gaints.pptx

DRL Vs Ranbaxy Pharmaceutical Gaints.pptx

1. Dr Reddy’s Laboratory Vs Ranbaxy Pharmaceuticals Kshitij Pathak- U113091 Lalip Nanda- U113092 Mayank Tabeck - U113093 Rakesh Kumar Jha - U113101 Rashmi Kulkarni- U113102 Rashmi Ranjan Nath-U113103 Shounak – U113111 Srishti Sen -U113112 Siddharth Padhee- U!13113

2. Pharmaceutical Industry Analysis Indian Companies Company Net Sales ( July 2013 $Bn) Employees Cipla 1.39 20,000 Dr Reddy’s Laboratories 1.14 16,300 Ranbaxy Labs 1.07 14,600 Aurobindo Pharma 0.92 8,635 Lupin Ltd 0.91 11,355 Sun Pharma 0.68 11,200 Novartis India 0.14 4,500 Global Companies Company Net Sales (2012 $ Bn) Employees Johnson & Johnson (USA) 67.2 117,000 Pfizer (USA) 58.9 91,000 Novartis (Switzerland) 56.7 115,000 Roche (Switzerland) 47.8 80,000 Merck (USA) 47.3 86,000 Sanofi (French) 46.4 113,000 GlaxoSmithKline (UK) 39.9 97,000

3. SWOT Analysis Strength Low cost of skilled manpower Access to large pool of highly trained scientists Strong marketing and distribution network Proven track record in design of high technology manufacturing devices Low cost of innovation, manufacturing and operations Weakness Stringent pricing regulations Poor transport and medical infrastructure Lack of data protection Very competitive environment Poor health insurance coverage Production of low quality drugs tarnishes image of industry abroad Low investment in innovative R&D

4. SWOT Analysis Threats Other low cost countries affecting demand Government regulations changing Expanding of Drugs Price Control Order Lack of investment in infrastructure Wage inflation R&D restricted by lack of animal testing and outdated patient office Counterfeiting threat. Opportunities Increase in per capita income Global demand for generics rising Increasing population with more sedentary lifestyle Increasing health insurance sector Significant investment from MNCs Medical tourism Cheap, diverse clinical trials Global outsourcing hub due to low cost of skilled labor

5. Before 1970 1970-1990 1990-2010 1.Increasing filing patent by Indian Companies. 2.Increasing adaption of new sales model Industry Growth Timeline 2010 and beyond

6. Trends in Indian Pharma Industry Amendments to Indian patent act 1970 , to make it TRIPS compliant. Increased incentives to domestic firms to conduct R&D.

7. To promote R&D(for future growth) as well as generic Business(for current profits), a robust organisational model was required. The organizational model should be able to differentiate bulk activities and generics from speciality and new drug discovery business DRL -Challenges

8. KEY METRICS FOR ORGANIZATIONAL STRUCTURE

9. Incorporated in 1961, as a family-owned business Chairman – Dr.Tsutomu Une ; CEO & Managing Director – Arun Sawhney Ranbaxy was facing many issues such as poor financial position, no major R&D breakthroughs, increasing price wars stiff competition in the generics market. In order to maintain its growth and market position, Ranbaxy needed an influx of fresh funds Daiichi Sankyo wanted to manufacture low cost generics because of Japan government’s new policy In June 2008, Daiichi Sankyo acquired over 51% stake in Ranbaxy Laboratories Ltd at Rs . 737 per share. Malvinder Singh sold out his stake of 34.8% to Daiichi Sankyo . The new entity is a significant milestone in the Ranbaxy’s mission of becoming a research-based international pharmaceutical company. RANBAXY LABORATORIES

10. PORTER’S FIVE FORCES Industry Competition Bargaining powers of suppliers DRL Cipla Glaxosmithkline Cadilla Dependence on organic chemicals Chemical Industry is very fragmented Suppliers have very low bargaining power Bargaining powers of buyers Barriers to entry Buyers are scattered and they for an entrepreneur in India. as such does not have power in the pricing of the products Government with it’s policies regulating pricing through the NPPA. Creating brand awareness is key for long term survival Threat of Substitute Products :Substitute to allopathic medicine are Ayurvedic and Homeopathic medicine ,but these are not much in practice in India PORTER’S 5 FORCES -RANBAXY

11. Ranbaxy’s competency of low cost manufacturing and Daiichi Sankyo’s competency of innovation will provide the new entity with a sustainable, long- term competitive advantage . Synergies across value chain to achieve maximum stakeholder value at every stage- with new model it is now among top 20 global pharma companies Ranbaxy is among largest generics companies in India and Daiichi Sankyo is among largest innovator companies in Japan Major Goals of the Global Hybrid Business model adopted in 2008: To achieve sustainable growth by ‘complementary business combination’ To enhance reach in emerging countries To accelerate innovative drug creation by optimizing value chain efficiency

12. ORGANIZATIONAL STRUCTURE OF RANBAXY

13. Total Revenues(in Rs.Cr )   DRL Ranbaxy 2001 944.9 1,785.67 2002 1,559.03 2,199.65 2003 1,594.87 3,215.54 2004 1,703.40 3,957.66 2005 1,569.97 3,938.88 2010 4,766.90 5,301.21 2011 5,384.50 6,370.25 2012 6,599.20 4,385.15 2013 8,676.30 6,228.72 DRL and RANBAXY – comparison of revenues

14. METRIC DR REDDY LAB RANBAXY DIFFERENTIATION Horizontal differentiation with control units Horizontal differentiation DECISION MAKING Decentralized Centralized HIERARCHY Flat with minimum chain of commands Flat STRUCTURE Multidivisional Structure Hybrid Structure INTEGRATING MECHANISM Liaison Role Team based DRL Vs RANBAXY Comparison of Organizational Structure

15. Having a centralized decision making system with a robust MIS system on the lines of reporting system of Merrill Lynch Centralization of R & D at corporate level to provide a more directed corporate strategy as done in case of HP Adoption of Matrix structure within the remaining units Combining CCS with emerging business for better integrating mechanism RECOMMENDATIONS

16. THANK YOU